"Selection of Patients Who Need Targeted Anti-Cancer Therapy"
- Identification of NSCLC (Non-small Cell Lung Cancer) patients for EGFR Tyrosine Kinase Inhibitors (TKIs) treatment
- Companion diagnostic test with Tarceva® (Erlotinib) and Tagrisso® (Osimertinib)
GenesWell™ddEGFR Mutation Test is a test for the presence of mutations in exons 18, 19, 20, and 21 of the EGFR, which is a biomarker of lung cancer. It can provide a basis for judging the effectiveness of chemotherapy by selecting patients in whom the targeted drug is effective after surgery.
GenesWell™ddEGFR Mutation Test can diagnose 46 kinds of mutation part present in the exon (3 on exon 18, 30 on exon 19, 10 on exon 20, 3 on exon 21) among EGFR gene. The panel includes the T790M mutation and C797S mutations, associated with second- and third-generation drug responses, respectively.
This diagnoses more mutations and provide doctors and patients with more accurate data than other products in the market.